ParoxysmalNocturnal Hemoglobinuria, or PNH, is an inherited condition that causes theimpaired production and premature death of red blood cells, mainly in the legs.The disease affects red blood cells that carry oxygen; platelets, which play amajor role in blood clotting; and white blood cells that are necessary for theorganism to fight infection. It can cause neurological disorders, includinghypertension, impaired consciousness, unconsciousness, fever, decreased bloodpressure, increased bleeding flow, and death. As this condition is an inheriteddisorder, most individuals with this disease do not develop any symptoms untilthey reach the age of 60 years old.
Symptomscommonly occur in individuals who have low plasma volume (less than eightymilligrams per deciliter of blood). However, some individuals with severeconditions may show symptoms even at the normal blood volume. Some of the morecommon symptoms include fatigue, leg pain, nausea, vomiting, anemia, weakness,blurred vision, nervousness, decreased vision, and difficulty concentrating. Insome cases, severe complications such as sepsis, thrombosis, and infection mayoccur with untreated paroxysmal nocturnal hemoglobinuria.
Owingto the rise of PNH across the globe the global paroxysmal nocturnalhemoglobinuria therapeutics market is witnessing significant demand. Forinstance, according to Johns Hopkins Medicine, PNH affects around 1-1.5individuals per million and is mainly traced in young adults. 30-45 years ofage is the median age of diagnosis, and occasional cases are diagnosed inadolescence and childhood. Moreover, key market players are working towards theapproval of newer and more advanced products for the market which is augmentingthe growth of the global paroxysmalnocturnal hemoglobinuria therapeutics market.
ReadMore : https://bit.ly/3xZvVFK
